.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,062,627

« Back to Dashboard

Details for Patent: 8,062,627

Title:Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
Abstract: A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.
Inventor(s): Aberg; Gunnar (Sarosota, FL), Morley; John (Richmond-upon-Thames, GB)
Assignee: Sunovion Pharmaceuticals Inc. (Marlborough, MA)
Filing Date:Mar 13, 2008
Application Number:12/048,068
Claims:1. A method of treating chronic bronchitis in a human in need of such therapy, the method comprising administering to the human a therapeutically effective amount of (R,R)-formoterol, or a pharmaceutically acceptable salt thereof, the (R,R)-formoterol containing at least 90% by weight of (R,R)-formoterol and less than 10% by weight of (S,S)-formoterol.

2. The method of claim 1, wherein the (R,R)-formoterol is administered by subcutaneous injection, intravenous infusion, inhalation, transdermal delivery or oral administration.

3. The method of claim 1, wherein the (R,R)-formoterol or pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.

4. The method of claim 1, wherein the (R,R)-formoterol is administered as the fumarate salt.

5. The method of claim 1, wherein the (R,R)-formoterol is administered as the tartrate salt.

6. The method of claim 1, wherein the (R,R)-formoterol is administered as the succinate salt.

7. The method of claim 2, wherein the (R,R)-formoterol is administered by inhalation and the amount administered is about 1 .mu.g to about 100 .mu.g per day, in single or divided doses.

8. The method of claim 7, wherein the amount administered is about 6 .mu.g to about 25 .mu.g per day, in single or divided doses.

9. The method of claim 8, wherein the amount administered is about 12 .mu.g to about 25 .mu.g per day, in single or divided doses.

10. The method of claim 9, wherein the amount is administered in from two to four divided doses.

11. The method of claim 2, wherein the (R,R)-formoterol is administered by oral administration and the amount administered is about 0.1 mg to about 1 mg per day.

12. A method of treating chronic bronchitis in a human in need of such therapy, the method comprising administering to the human a therapeutically effective amount of (R,R)-formoterol, or a pharmaceutically acceptable salt thereof, the (R,R)-formoterol containing at least 90% by weight of (R,R)-formoterol and less than 10% by weight of (S, S)-formoterol, and wherein the amount of (R,R)-formoterol is sufficient to treat chronic bronchitis, but insufficient to cause adverse effects associated with racemic formoterol.

13. The method of claim 12, wherein the (R,R)-formoterol is administered by subcutaneous injection, intravenous infusion, inhalation, transdermal delivery or oral administration.

14. The method of claim 12, wherein the (R,R)-formoterol or pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.

15. The method of claim 12, wherein the (R,R)-formoterol is administered as the fumarate salt.

16. The method of claim 12, wherein the (R,R)-formoterol is administered as the tartrate salt.

17. The method of claim 12, wherein the (R,R)-formoterol is administered as the succinate salt.

18. The method of claim 12, wherein the (R,R)-formoterol is administered by inhalation and the amount administered is about 1 .mu.g to about 100 .mu.g per day, in single or divided doses.

19. The method of claim 18, wherein the amount administered is about 6 .mu.g to about 25 .mu.g per day, in single or divided doses.

20. The method of claim 19, wherein the amount administered is about 12 .mu.g to about 25 .mu.g per day, in single or divided doses.

21. The method of claim 20, wherein the amount is administered in from two to four divided doses.

22. The method of claim 13, wherein the (R,R)-formoterol is administered by oral administration and the amount administered is about 0.1 mg to about 1 mg per day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc